Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression
- PMID: 17958893
- PMCID: PMC2148054
- DOI: 10.1186/1477-5751-6-9
Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression
Abstract
Background: The matrix metalloproteinases (MMPs) are enzymes that cleave various components of the extracellular matrix (ECM) and basement membranes. MMPs are expressed in melanocytes and their overexpression has been linked to tumor development, progression and metastasis. At the genetic level, the following functional promoter polymorphisms are known to modify the gene transcription: -1306 C/T and -735 C/T in the MMP2 gene, and -1171 5A/6A in the MMP3 gene. Functional polymorphisms in MMP genes' promoter regions may modulate the risk for melanoma progression.
Methods: We evaluated MMP2 and MMP3 germline polymorphisms in a group of 1002 melanoma patients using PCR-based methods, including fragment size analysis and melting temperature profiles. Two-sided Chi-Square, Cochran-Armitage tests for trend, Fisher's exact tests, and Kendall's Tau tests were performed to evaluate the associations between genotype and various clinical and epidemiologic factors. Multivariate analyses were conducted using logistic regression, adjusting for known melanoma confounders such as age, sex, phenotypic index, moles, freckles, and race. Survival estimates were computed using the Kaplan-Meier method and differences in survival were assessed using the log rank test.
Results: All genotypes were in Hardy-Weinberg equilibrium. After adjustment for age, sex and phenotypic characteristics of melanoma risk, no significant associations were identified with the clinical, pathological, and epidemiological variables studied. The melting profile for MMP2 -735 C/T identified a new change in one sample. A new PCR-amplification followed by direct sequencing confirmed a heterozygote G to A substitution at position -729.
Conclusion: This study does not provide strong evidence for further investigation into the role of the MMP2 and MMP3 variants in melanoma progression.
Figures

Similar articles
-
Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India.Urol Oncol. 2013 Feb;31(2):247-54. doi: 10.1016/j.urolonc.2011.01.001. Epub 2011 Jul 23. Urol Oncol. 2013. PMID: 21784671
-
Polymorphisms of genes involved in extracellular matrix remodeling and abdominal aortic aneurysm.J Vasc Surg. 2012 Jan;55(1):171-179.e2. doi: 10.1016/j.jvs.2011.07.051. Epub 2011 Nov 16. J Vasc Surg. 2012. PMID: 22094117
-
Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival.BMC Cancer. 2012 Mar 28;12:121. doi: 10.1186/1471-2407-12-121. BMC Cancer. 2012. PMID: 22455335 Free PMC article.
-
Matrix metalloproteinase (MMP) -2, -7 and -9 promoter polymorphisms in colorectal cancer in ethnic Kashmiri population - A case-control study and a mini review.Gene. 2016 Sep 1;589(1):81-89. doi: 10.1016/j.gene.2016.05.028. Epub 2016 May 21. Gene. 2016. PMID: 27222481 Review.
-
Matrix Metallopeptidase 3 Polymorphisms: Emerging genetic Markers in Human Breast Cancer Metastasis.J Breast Cancer. 2020 Feb;23(1):1-9. doi: 10.4048/jbc.2020.23.e17. J Breast Cancer. 2020. PMID: 32140265 Free PMC article. Review.
Cited by
-
No Association of Matrix Metalloproteinase [MMP]-2 (-735C > T) and Tissue Inhibitor of Metalloproteinase [TIMP]-2 (-418G > C) Gene Polymorphisms with Cervical Cancer Susceptibility.Indian J Clin Biochem. 2013 Jan;28(1):13-8. doi: 10.1007/s12291-012-0237-4. Epub 2012 Jul 3. Indian J Clin Biochem. 2013. PMID: 24381415 Free PMC article.
-
Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression.Melanoma Res. 2012 Apr;22(2):169-75. doi: 10.1097/CMR.0b013e32834fc46b. Melanoma Res. 2012. PMID: 22198560 Free PMC article.
-
Missense polymorphisms in matrix metalloproteinase genes and skin cancer risk.Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3551-7. doi: 10.1158/1055-9965.EPI-08-0606. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 19064570 Free PMC article.
-
Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis.PLoS One. 2012;7(2):e31251. doi: 10.1371/journal.pone.0031251. Epub 2012 Feb 14. PLoS One. 2012. PMID: 22348060 Free PMC article.
-
Investigation of the role of MMP3 -1171insA polymorphism in cutaneous malignant melanoma - a preliminary study.Biotechnol Biotechnol Equip. 2014 Sep 3;28(5):904-910. doi: 10.1080/13102818.2014.947694. Epub 2014 Nov 13. Biotechnol Biotechnol Equip. 2014. PMID: 26019576 Free PMC article.
References
-
- Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GN. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol. 2000;191:245–256. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH632>3.0.CO;2-#. - DOI - PubMed
-
- Vaisanen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol. 1996;180:283–289. doi: 10.1002/(SICI)1096-9896(199611)180:3<283::AID-PATH662>3.0.CO;2-3. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous